Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of anaplastic lymphoma kinase (ALK) comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets…

The approval of the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) for recurrent and metastatic disease has transformed the SCCHN therapy market, which is…

To determine the trade-offs across key biosimilar attributes that surveyed medical oncologists are willing to make when considering which biosimilar to prescribe, we included an adaptive choice-…

Antibody-drug conjugates have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of…

In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…

In 2021, sales of branded MAb biologics in oncology exceeded $36 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5…

Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…

Bispecific therapies represent a class of drug with two binding sites directed at two different antigens or epitopes. This dual action makes bispecific therapies a promising approach to improve…

The treatment landscape for squamous cell carcinoma of the head and neck (SCCHN) witnessed a major change in 2019 with the approval of Merck & Co.’s Keytruda for untreated recurrent or metastatic…

Acute myeloid leukemia (AML) is the most common form of leukemia in adults and has historically been associated with poor five-year overall survival rates. In recent years, the AML treatment…

China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved for treatment—trastuzumab (Roche’s Herceptin,…

In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…